| Filed On | Filing |
|---|---|
| 06 Nov 2026 |
8-K: Other Events
We have acted as counsel to Zenas BioPharma, Inc., a Delaware corporation (the “Company”), in connection with the Registration Statement on Form S-3ASR (the “Registration Statement”) filed on October 8, 2025 by the Company with the Secur... |
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
- PDUFA target action date of May 27, 2027, following FDA acceptance of Obexelimab BLA submission for the treatment of IgG4-RD in second quarter 2026 - |
| 13 Oct 2026 |
8-K: Regulation FD Disclosure
Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease |
| 13 Aug 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation
- Obexelimab BLA submission for the treatment of IgG4-RD accepted by FDA; PDUFA target action date of May 27, 2027 - |
| 13 May 2026 |
8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation +1 more
- Obexelimab marketing applications for the treatment of IgG4-RD on-target for submission to the FDA this quarter and the EMA in H2 2026 based on the Phase 3 INDIGO IgG4-RD trial results - |
| 31 Mar 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +1 more
Note: This Cross-Reference Table shall not, for any purpose, be deemed to be a part of the Indenture. |
| 16 Mar 2026 |
8-K: Results of Operations and Financial Condition
- Obexelimab marketing applications for the treatment of IgG4-RD expected to be submitted to the FDA in Q2 2026 and the EMA in H2 2026 based on the Phase 3 INDIGO trial results - |
| 13 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
The compensation philosophy of Zenas BioPharma, Inc. (the “Parent”, and together with its direct and indirect subsidiaries, the “Company”) is to attract, motivate, retain and reward employees with base pay, short-term and long-term incen... |
| 05 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) |
| 15 Dec 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
This agreement, including the additional terms and conditions for certain countries, set forth in the appendix attached hereto (the “Appendix” and, together with this Global Restricted Stock Unit Agreement, the “Agreement”) evidences a g... |
| 12 Nov 2025 |
8-K: Results of Operations and Financial Condition
- Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 - |
| 27 Oct 2025 |
8-K: Regulation FD Disclosure; Other Events
- Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 - |
| 08 Oct 2025 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +3 more
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 7, 2025, by and among Zenas BioPharma, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Exhibit A and Exhibit B attached to thi... |
| 02 Sep 2025 |
8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +2 more
- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease - |
| 12 Aug 2025 |
8-K: Results of Operations and Financial Condition
- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - |
| 12 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 04 Jun 2025 |
8-K: Regulation FD Disclosure
1 Zenas BioPharma Corporate Presentation June 2025 Enabling patients with autoimmune diseases to reimagine life |
| 15 May 2025 |
8-K: Results of Operations and Financial Condition
- Topline results from pivotal Phase 3 INDIGO trial in Immunoglobulin G4-Related Disease expected around year-end 2025 - |
| 05 Feb 2025 |
8-K: Results of Operations and Financial Condition
Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases |
| 02 Dec 2024 |
8-K: Regulation FD Disclosure
1 Zenas BioPharma Corporate Presentation December 2024 Enabling patients with autoimmune diseases to reimagine life |
Loading...